重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗前后银屑病患者血清脂联素水平的变化

发布时间：2018-10-22 19:00

【摘要】：目的:研究分析注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白(商品名,益赛普)对银屑病患者血清脂联素水平的影响。方法:将28例寻常性银屑病患者(银屑病组)及28例年龄、性别和体重指数(BMI)相匹配的健康志愿者(健康对照组)纳入研究,银屑病严重性评级指标采用银屑病皮损面积和严重程度指数(PASI)及体表受累面积(BSA)评分,所有患者均给予益赛普50 mg,皮下注射,每周1次。对所有银屑病患者治疗前、治疗后12周、24周与健康对照组的血清脂联素水平进行随访检测。结果:银屑病组血清脂联素水平较健康对照组明显降低,差异有统计学意义(P0.05)。经过12周的益赛普治疗后,银屑病组血清脂联素水平较治疗前升高,但差异无统计学意义(P0.05),经过24周的益赛普治疗后,银屑病组血清脂联素水平较治疗前及治疗12周后均有明显升高,差异有统计学意义(P0.05),与健康对照组相比差异无统计学意义。结论:脂联素与银屑病的发病可能具有相关性,使用益赛普治疗银屑病,可降低银屑病患者代谢综合征的发生率。
[Abstract]:Aim: to study the effect of recombinant human tumor necrosis factor receptor-antibody fusion protein (Isop) on serum adiponectin levels in patients with psoriasis. Methods: 28 patients with psoriasis vulgaris (psoriasis group) and 28 healthy volunteers (healthy control group) matched with age, sex and body mass index (BMI) (BMI) were included in the study. Psoriasis severity index (PASI) and surface involvement area (BSA) score were used to evaluate psoriasis severity. All patients were subcutaneously injected with Isopril 50 mg, once a week. The serum adiponectin levels of all psoriatic patients before treatment, 12 weeks and 24 weeks after treatment were followed up. Results: the serum adiponectin level in psoriasis group was significantly lower than that in healthy control group (P0.05). The serum adiponectin level in psoriatic group was higher than that before treatment, but the difference was not statistically significant (P0.05). After 24 weeks of treatment, the serum adiponectin level in psoriasis group was higher than that before treatment (P0.05). The serum adiponectin level in psoriasis group was significantly higher than that before treatment and 12 weeks after treatment (P0.05), and there was no significant difference compared with the healthy control group. Conclusion: adiponectin may be associated with the pathogenesis of psoriasis. The treatment of psoriasis with Isop can reduce the incidence of metabolic syndrome in psoriatic patients.
【作者单位】：大连市皮肤病医院银屑病专科;
【分类号】：R758.63

【相似文献】